← Eichor
Study identifier: NCT07128927 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Assessing the Feasibility of Web-based Insomnia Treatment Among Prostate Cancer Survivors

Condition: Insomnia  ·  Sponsor: Georgetown University

PhaseNA
Planned participants40
Who can joinMale, 21 Years to no upper limit
Healthy volunteersNo

About this study

This pilot study will recruit Black/African American prostate cancer survivors into a clinical trial and will randomize each person to 1 of 2 possible treatments - an internet-based treatment for insomnia called Sleep Healthy Using the Internet (SHUTi) or an educational website. SHUTi provides the treatment - cognitive behavioral therapy for insomnia - across 6 lessons, while the educational website is like an online patient brochure. The study will examine the feasibility of SHUTi to improve sleep and well-being among Black prostate cancer survivors. It will also examine whether SHUTi is acceptable to these survivors and will compare the effect of SHUTi versus the educational website on insomnia and non-insomnia patient-reported outcomes.

This description comes directly from the study's public registry record.

Talk to the study team

Traci Bethea  ·  202-687-5367  ·  siestap@georgetown.edu

Always discuss trial participation with your own doctor first.

Locations (1)

Georgetown Lombardi Comprehensive Cancer CenterWashington D.C., District of Columbia, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07128927